Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Reducing metastases stiffness by targeting fibroblasts improves therapeutic outcome in colorectal cancer [Tissue]

ABSTRACT: Analysis of colorectal primary tumors (pTU) and liver metastases (LM) tissue samples from patients and identify corresponding gene expression signatures

ORGANISM(S): Homo sapiens

PROVIDER: GSE145429 | GEO | 2020/05/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Reducing metastases stiffness by targeting fibroblasts improves therapeutic outcome in colorectal cancer [Cells]

Project description:Analysis of primary fibroblasts isolated from human colorectal primary tumors(CAFs) and liver metastases(MAFs) and identify corresponding gene expression signatures

2020-05-01 | GSE145428 | GEO

Reducing metastases stiffness by targeting fibroblasts improves therapeutic outcome in colorectal cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-05-01 | GSE145432 | GEO

Reducing metastases stiffness by targeting fibroblasts improves therapeutic outcome in colorectal cancer

Project description:Reducing metastases stiffness by targeting fibroblasts improves therapeutic outcome in colorectal cancer

| PRJNA607204 | ENA

Reducing metastases stiffness by targeting fibroblasts improves therapeutic outcome in colorectal cancer [Tissue]

Project description:Reducing metastases stiffness by targeting fibroblasts improves therapeutic outcome in colorectal cancer [Tissue]

| PRJNA607210 | ENA

Reducing metastases stiffness by targeting fibroblasts improves therapeutic outcome in colorectal cancer [Cells]

Project description:Reducing metastases stiffness by targeting fibroblasts improves therapeutic outcome in colorectal cancer [Cells]

| PRJNA607211 | ENA

Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities

Project description:Advanced colorectal cancer (CRC), a leading cause of death worldwide, is often accompanied by the development of liver metastases (LM), as well as skeletal muscle (SkM) wasting, i.e. cachexia. Despite affecting the majority of CRC patients, cachexia remains understudied and uncured. Moreover, only a single model of LM associated with CRC has been developed for the study of cachexia. Here we examined differential gene expression of skeletal muscles deriving from subcutaneous and metastatic C26 tumor hosts. Tumor hosts displaying LM experienced exacerbated muscle wasting compared to tumor hosts without LM.

2020-04-18 | GSE142455 | GEO

Liver metastases originating from 4 colorectal cancer patients (CRC-LM).

Project description:Using liver metastases from 4 colorectal cancer patients (CRC-LM), we explored one receptor: EGFR whose signaling triggers cell proliferation and is exacerbated in many tumors.

2023-06-14 | GSE217414 | GEO

Proteomic Signatures of Myeloid Derived Suppressor Cells from Liver and Lung Metastases Reveal Functional Divergence and Potential Therapeutic Targets

Project description:Myeloid Derived Suppressor Cells (MDSCs) promote immunosuppressive activities in the tumor microenvironment (TME), resulting in increased tumor burden and diminishing the anti-tumor response of immunotherapies. While primary and metastatic tumors are typically the focal points of therapeutic development, the immune cells of the TME are uniquely programmed by the tissue of the metastatic site. In particular, MDSCs are programmed uniquely within different organs in the context of tumor progression. Given that MDSC plasticity is shaped by the surrounding environment, the proteome of MDSCs from different metastatic sites are hypothesized to be unique. A bottom-up proteomics approach using Sequential Window Acquisition of All Theoretical Mass Spectra (SWATH-MS) was used to quantify the proteome of CD11b+ cells derived from murine liver metastases (LM) and lung metastases (LuM). A comparative proteomics workflow was employed to compare MDSC proteins from LuM (LuM-MDSC) and LM (LM-MDSC) while also elucidating common signaling pathways, protein function, and possible drug-protein interactions.

2021-11-03 | PXD023337 | Pride

Comparison of gene expression profiles between the CD110+ tumor initiating cells from primary colorectal tumors and their liver metastases.

Project description:We established an in vivo model of organ-specific colorectal cancer metastasis and demonstrated that the CD110+ tumor initiating cells contribute for colorectal liver metastasis. To gain a deeper understanding of its metastatic capacity, we performed a genome-wide transcriptome analysis on the CD110+ tumor cells derived from primary colon xenografts and their matched liver metastases. Results provide important information of the responses of the CD110+ cells during the process of liver colonization. Total RNA obtained from the CD110+ cells sorted from primary colorectal tumors (CRC102-PT and CRC108-PT) compared to those from the corresponding liver metastases (CRC102-LM and CRC108-LM).

2015-01-01 | E-GEOD-64595 | biostudies-arrayexpress

Colorectal Liver Metastases

Project description:mRNA sequencing by Lexogen Quantseq 3 prime of colorectal liver metastases

| PRJEB35154 | ENA